Arrivent BioPharma, Inc.

As of October 3, 2025, Arrivent BioPharma, Inc. shows a mildly bearish trend with a 10.04% weekly return, outperforming the S&P 500's 1.09%, but has a year-to-date return of -25.53% compared to the S&P 500's 14.18%.

As of September 8, 2025, Arrivent BioPharma, Inc. is in a mildly bearish trend, indicated by bearish signals from technical indicators and underperformance against the S&P 500, with year-to-date and one-year returns of -30.26% and -21.24%, respectively.

As of June 11, 2025, Arrivent BioPharma, Inc. shows a mildly bullish trend based on weekly indicators, despite short-term bearish signals from daily moving averages.

Arrivent BioPharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $64 million and a market cap of $854.63 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -39.74%.

As of Jun 18, Arrivent BioPharma, Inc. has a market capitalization of 854.63 million and reported net sales of 0.00 million with a net profit of -127.45 million over the last four quarters. Shareholder's funds were valued at 257.65 million, and total assets amounted to 274.94 million.